Horizon's booth at the American Society of Nephrology conference featured a pipework depiction of the body's organs.

Hori­zon dou­bles down on Krys­texxa mar­ket­ing to physi­cians with ‘green stuff’ im­agery

Hori­zon’s re­cent la­bel makeover for 12-year-old gout med Krys­texxa is breath­ing new life in­to the drug — and its mar­ket­ing ef­forts.

In Ju­ly, Hori­zon picked up a new FDA-ap­proved la­bel for Krys­texxa co-ad­min­is­tered with methotrex­ate. The com­bi­na­tion study showed in­creased ef­fec­tive­ness from 42% to 71% and a mas­sive drop in in­fu­sion re­ac­tions, down to 4% from a pre­vi­ous 31% of pa­tients re­port­ing re­ac­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.